


Utilization Management Policy Name: Somatostatin Analogs – NC Standard

Restricted Product(s):

- Bynfezia Pen[™] (octreotide)
- Mycapssa® (octreotide) delayed-release capsules
- Sandostatin[®] (octreotide)
- Sandostatin LAR[®] (octreotide)
- Somatuline[®] Depot (lanreotide)

FDA Approved Use:

- Bynfezia Pen
 - Reduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) [somatomedin C] in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses
 - o Treatment of severe diarrhea/flushing episodes associated with metastatic carcinoid tumors in adult patients
 - Treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) in adult patients
- Mycapssa
 - Long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
- Sandostatin
 - Reduction in blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels.
 - Symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease.
 - Treatment of the profuse watery diarrhea associated with VIP-secreting tumors
- Sandostatin LAR



- Treatment in patients who have responded to and tolerated Sandostatin subcutaneous injection for acromegaly, severe diarrhea/flushing episodes associated with metastatic carcinoid tumors, and/or profuse watery diarrhea associated with VIP-secreting tumors.
- Somatulatine Depot
 - For the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
 - For the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival
 - For the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analogue rescue therapy

Criteria for INITIAL Approval of Restricted Product(s):

- 1. The patient has a diagnosis of acromegaly; AND
 - a. The use of the requested agent is for adjunctive therapy with irradiation to alleviate acromegaly symptoms; OR
 - b. The patient had an inadequate response to surgery or pituitary irradiation defined by ONE of the following documented parameters:
 - i. Growth hormone level > 5 ng/mL; **OR**
 - ii. IGF-1 level > 1.9 U/mL for males or > 2.2 U/mL for females; OR
 - c. Patient is not a candidate for surgical resection; OR
- 2. The patient has a diagnosis of carcinoid tumor, locally advanced/metastatic gastroenteropancreatic neuroendocrine tumor or poorly differentiated (high-grade)/large or small cell neuroendocrine tumor, pancreas islet cell neuroendocrine tumor, or vasoactive intestinal polypeptidoma; **AND**
 - a. ONE of the following:
 - I. The patient will be using the medication for symptom control for carcinoid syndrome or hormone hypersecretion; OR
 - II. The patient is not a candidate for surgical resection or radiation therapy; AND
- 3. If the requested agent is Bynfezia Pen (octreotide) or Mycapssa (octreotide DR capsules), the patient has tried and failed or has a contraindication to generic octreotide injection; **AND**
- 4. If the requested agent is Mycapssa (octreotide DR capsules), the patient has been adequately controlled and tolerated an octreotide or lanreotide injection; **AND**
- 5. For formularies that exclude (non-formulary) the requested medication, Non-formulary Exception Criteria applies (outlined below)*

Duration of Approval: 24 weeks



Criteria for CONTINUED Approval of Restricted Product(s):

- 1. The patient has been approved through the initial BCBSNC coverage criteria (above) and is continuing therapy for one of the indications in the initial coverage criteria; **AND**
- 2. Has objective markers for improvement, exemplified by:
 - a. Growth hormone (GH) level < 5 ng/mL; OR
 - b. IGF-1 level < 1.9 U/mL for a male or < 2.2 U/mL for a female: OR
 - c. Clinical improvement in conditions related to the approved diagnosis:
 - i. Reduction in tumor size; OR
 - ii. Decreased headaches; OR
 - iii. Improved cardiovascular symptoms; **OR**
 - iv. Improved respiratory symptom.

Duration of Approval: 1095 days (3 years)

*Non-formulary Exception Criteria

Non-Formulary Exception criteria applies on formularies which exclude requested product(s). Satisfactory completion of criteria points (above) may satisfy some, or all, portions of the Non-Formulary Exception Criteria. This criteria is summarized as:

- a) Request must be for an FDA approved indication; AND
- b) Patient must have a trial and failure of up to **TWO** formulary medications or a clinical contraindication/intolerance to those medications not tried.

References: all information referenced is from FDA package insert unless otherwise noted below.

- 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^{®1}) for Neuroendocrine Tumors V.1.2019. National Comprehensive Cancer Network, Inc. 2019. Accessed August 22, 2019
- 2. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3933.



Quantity Limitations: quantity limitations apply to brand and associated generic products.

Medication	Quantity per Day (unless specified)
Mycapssa (octreotide) delayed-release 20 mg	4 capsules

Quantity Limit Exception Criteria:

- 1. The quantity (dose) requested is for documented titration purposes at the initiation of therapy (authorization for a 90 day titration period); AND
- 2. The prescribed dose cannot be achieved using a lesser quantity of a higher strength; AND
- 3. The quantity (dose) requested does not exceed the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer's product insert; **OR**
- 4. If the quantity (dose) requested exceeds the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer's product insert, then the prescriber must submit documentation in support of therapy with a higher dose for the intended diagnosis (submitted documentation may include medical records OR fax form which reflects medical record documentation that shows the length of time the requested dose has been used, and what other medications and doses have been tried and failed).

*Non-formulary Exception Criteria

Non-Formulary Exception criteria applies on formularies which exclude requested product(s). Satisfactory completion of criteria points (above) may satisfy some, or all, portions of the Non-Formulary Exception Criteria. This criteria is summarized as:

- c) Request must be for an FDA approved indication; AND
- d) Patient must have a trial and failure of up to **TWO** formulary medications or a clinical contraindication/intolerance to those medications not tried.

References: all information referenced is from FDA package insert unless otherwise noted below.

Policy Implementation/Update Information:

July 2020: Original utilization management criteria issued. Combined Bynfezia Pen[™] - Sandostatin[®] & Somatuline[®] criteria. Retired both.



Non-Discrimination and Accessibility Notice

Discrimination is Against the Law

- Blue Cross and Blue Shield of North Carolina ("Blue Cross NC") complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.
- Blue Cross NC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

Blue Cross NC:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
 - Qualified interpreters
 - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
 - Qualified interpreters
 - Information written in other languages
- If you need these services, contact Customer Service **1-888-206-4697**, TTY and TDD, call **1-800-442-7028**.
- If you believe that Blue Cross NC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
 - Blue Cross NC, PO Box 2291, Durham, NC 27702, Attention: Civil Rights Coordinator- Privacy, Ethics & Corporate Policy Office, Telephone 919-765-1663, Fax 919-287-5613, TTY 1-888-291-1783 <u>civilrightscoordinator@bcbsnc.com</u>
- You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, Civil Rights Coordinator Privacy, Ethics & Corporate Policy Office is available to help you.
- You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of



Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 **1-800-368-1019**, **800-537-7697** (TDD). Complaint forms are available at <u>http://www.hhs.gov/ocr/office/file/index.html</u>.

• This Notice and/or attachments may have important information about your application or coverage through Blue Cross NC. Look for key dates. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call Customer Service **1-888-206-4697**.

ATTENTION: If you speak another language, language assistance services, free of charge, are available to you. Call 1-888-206-4697 (TTY: 1-800-442-7028).

ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-888-206-4697 (TTY: 1-800-442-7028).

注意:如果您講廣東話或普通話,您可以免費獲得語言援助服務。請致電 1-888-206-4697 (TTY: 1-800-442-7028)。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-888-206-4697 (TTY: 1-800-442-7028).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1-888-206-4697 (TTY: 1- 800-442-7028)번으로 전화해 주십시오.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-888-206-4697 (ATS : 1-800-442-7028).

ملحوظة: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-888-206-4697. المبرقة الكاتبة: 7028-442-7028.

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1-888-206-4697 (TTY: 1-800-442-7028).

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-888-206-4697 (телетайп: 1-800-442-7028).



PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-888-206-4697 (TTY: 1-800-442-7028).

સુચના: જો તમે ગુજરાતી બોલતા હો, તો નિ:સુલ્કુ ભાષા સહાય સેવાઓ તમારા માટે ઉપલબ્ધ છે. ફોન કરો 1-888-206-4697 (TTY: 1-800-442-7028).

ចំណាំ៖ ប្រសិនបើលោកអ្នកនិយាយជាភាសាខ្មែរ សេវាកម្មជំនួយផ្នែកភាសាមានផ្តល់ជូនសម្រាប់លោកអ្នកដោយមិនគិតថ្លៃ។ សូមទំនាក់ទំនងតាមរយ:លេខ៖ 1-888-206-4697 (TTY: 1-800-442-7028)។

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-888-206-4697 (TTY: 1-800-442-7028).

ध्यान दें: यदि आप हिन्दी बोलते हैं तो आपके लिए मुफ्त में भाषा सहायता सेवाएं उपलब्ध हैं। 1-888-206-4697 (TTY: 1-800-442-7028) पर कॉल करें।

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 1-888-206-4697 (TTY: 1-800-442-7028). 注意事項:日本語を話される場合、無料の言語支援をご利用いただけます。1-888-206-4697 (TTY: 1-800-442-7028) まで、お電話にてご連絡ください。